BAD sensitizes breast cancer cells to docetaxel with increased mitotic arrest and necroptosis

Breast cancer patients are commonly treated with taxane (e.g. docetaxel) chemotherapy, despite poor outcomes and eventual disease relapse. We previously identified the Bcl-2-associated death promoter (BAD) as a prognostic indicator of good outcome in taxane-treated breast cancer patients. We also de...

Descripción completa

Detalles Bibliográficos
Autores principales: Mann, Jasdeep, Yang, Ning, Montpetit, Rachel, Kirschenman, Raven, Lemieux, Hélène, Goping, Ing Swie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962214/
https://www.ncbi.nlm.nih.gov/pubmed/31942016
http://dx.doi.org/10.1038/s41598-019-57282-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962214/
https://www.ncbi.nlm.nih.gov/pubmed/31942016
http://dx.doi.org/10.1038/s41598-019-57282-1

Ejemplares similares